Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma
出版年份 2019 全文链接
标题
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma
作者
关键词
-
出版物
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages 1-5
出版商
Informa UK Limited
发表日期
2019-09-16
DOI
10.1080/17512433.2019.1665026
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
- (2017) Michal Šmahel INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
- (2017) Laura C. Cappelli et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- The Treatment of Actinic Keratoses—The Rule Rather Than the Exception
- (2017) Bobbak Mansouri et al. JAMA Dermatology
- Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC)
- (2016) Anthony Jarkowski et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma
- (2016) Igor N. Ivashko et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Consensus for Nonmelanoma Skin Cancer Treatment, Part II
- (2015) Arielle N. B. Kauvar et al. DERMATOLOGIC SURGERY
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression as a potential predictive biomarker
- (2015) Alberto Fusi et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012
- (2015) Howard W. Rogers et al. JAMA Dermatology
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- (2013) Aurélien Marabelle et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation